drugset / Trial / NCT07333742

A Clinical Study to See How the Body Handles and How Safe a Combination Tablet of Gemigliptin, Dapagliflozin, and Metformin 50/10/1000mg is Compared to Taking Gemigliptin 50mg Separately With Dapagliflozin/Metformin 10/1000mg in Healthy Adults After a Meal

NCT07333742

Phase 1 Completed 50 enrolled LG Chem
RandomizedCrossoverOpen-labelOther

Summary

Bioequivalence study for the fixed-dose combination of gemigliptin/dapagliflozin/metformin 50/10/1000 mg under fed conditions in healthy volunteers

Timeline

Start
2025-09-29
Primary completion
2025-11-27
Completion
2025-11-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Dapagliflozin Small molecule 10 mg Oral
Subject Gemigliptin Small molecule 50 mg Oral
Subject Metformin Small molecule 1000 mg Oral

Indications

No indication recorded.